Phencyclidine Rapid Test (DTS140)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
25T
Sample
urine
Intended Use
The CD One Step Phencyclidine Screening Test is a rapid, qualitative immunoassay for the detection of Phencyclidine in urine. The cutoff concentration for this test is 25 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA).
Storage
Store at room temperature (15-28°C). Do not freeze. Refer to expiration date for stability.
Sensitivity
The CD Phencyclidine Test detects PCP at a cutoff concentration equal to or greater than 25 ng/mL.

Citations


Have you cited DTS140 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia

BEHAVIOURAL PHARMACOLOGY

Authors: Seillier, Alexandre; Giuffrida, Andrea

Social withdrawal should not be considered a direct measure of the negative symptoms of schizophrenia as it may result not only from asociality (primary negative symptom) but also from other altered processes such as anxiety. To understand the contribution of these two factors to social deficit, we investigated whether the social withdrawal observed in the subchronic phencyclidine (PCP) rat model of schizophrenia could be attributed to increased anxiety. Compared to saline controls, PCP-treated rats (5 mg/kg, twice daily for 7 days, followed by a washout period) spent significantly less time in social interaction, but did not show anxiety-like behaviors in different relevant behavioral paradigms. In addition, their social deficit was not affected by a behavioral procedure known to reduce anxiety-like behavior (repeated exposure to the same partner) nor by systemic administration of the classical anxiolytic diazepam. In contrast, PCP-induced social withdrawal was reversed by the cannabinoid agonist CP55,940, a drug with known anxiogenic properties. Furthermore, when using the social approach task, PCP-treated animals performed similarly to control animals treated with diazepam, but not to those treated with the anxiogenic compound pentylenetetrazole. Taken together, our results indicate that PCP-induced social withdrawal cannot be attributed to increased anxiety. These data are discussed in the context of primary versus secondary negative symptoms and the deficit syndrome of schizophrenia. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.

Potential benefit of lamotrigine in managing ketamine use disorder

MEDICAL HYPOTHESES

Authors: Huang, Ming-Chyi; Chen, Lian-Yu; Chen, Chih-Ken; Lin, Shih-Ku

Ketamine is an anesthetic derivative of phencyclidine (PCP; 'Angel dust') with dissociative, analgesic and psychedelic properties. Ketamine has become a popular recreational drug of abuse in many parts of the world in recent years. The preclinical studies demonstrate the reinforcing effects of ketamine and long-term ketamine abuse induces a delayed and persistent upregulation of dopamine system. In humans, there have been concerns about its liability to development of addiction. The dilemma of mental professionals in managing the treatment-seeking ketamine abusers comes from a lack of effective pharmacotherapy. Limiting evidence showed that lamotrigine, which inhibits glutamate release, is effective to reduce cocaine craving. We propose that lamotrigine might be beneficial for managing ketamine use disorder clinically. We also reported one case of ketamine use disorder who experienced a great reduction in craving and ketamine use after taking lamotrigine. Although the mechanisms underlying neuroadaptation and reward related to ketamine are not entirely clear, future clinical trials are needed to advance our understanding of the benefit yielded by lamotrigine to treat ketamine use disorder. (C) 2015 Published by Elsevier Ltd.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket